Tern Therapeutics Presents Long Term Data

Late last week, Mr Robert Henderson, Consultant Paediatric Ophthalmologist at GOSH presented promising long-term safety and efficacy data from the Tern Therapeutics clinical trial of TTX-381 gene therapy for ocular CLN2 Batten disease during the Association for Research in Vision and Ophthalmology (ARVO) 2026 conference.

More detail about this exciting data can be found here: https://www.terntx.com/blog/Blog%20Post%20Title%20One-3zaa9-zlxng-67tfc-cg52h-7k64z